Shares of DexCom Inc. DXCM rallied 3.79% to $73.38 Wednesday, on what proved to be an all-around positive trading session for ...

Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following ...

HCPs see CGM as the 'standard of care': Half of all HCPs felt CGM should be the standard of care for people with Type 2 diabetes whether they were using insulin to manage the condition or not. 96% of ...

Operating income (non-GAAP) decreased to $209.5 million from $242.7 million. DexCom reported mixed earnings, with revenue surpassing estimates but earnings per share falling short. DexCom ...

The FDA cited issues with DexCom's response to prior inspection findings, known as Form 483 observations. The inspections took place at the San Diego facility between October 21 and November 7 ...

17:02 EST DexCom (DXCM) falls 7% to $71.99 after receiving warning letter from FDA See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze, and streamline your ...

The announcement came after a quarter where DexCom reported a 7% increase in sales, though net income declined significantly alongside a reduction in earnings per share. During the past quarter ...

Investors with a lot of money to spend have taken a bullish stance on DexCom (NASDAQ:DXCM). And retail traders should know. We noticed this today when the positions showed up on publicly available ...

7.9% per year. Even after the forecast slowdown in growth, it seems obvious that DexCom is also expected to grow faster than the wider industry.